Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTS3497 in MTAP-deficient advanced solid tumors and lymphomas
NCT06971523Phase 2Recruiting
- Sponsor
- CytosinLab Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CTS3497 in solid tumor, lymphoma, Esophageal Squamous Cell Carcinoma (ESCC), pancreatic adenocarcinoma (PDAC), biliary tract cancer (BTC), sponsored by CytosinLab Therapeutics. Started Dec 2024; status: recruiting.
02
Drugs
CTS3497
03
Conditions
solid tumorlymphomaEsophageal Squamous Cell Carcinoma (ESCC)pancreatic adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06971523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971523.